Home Sulfos N-[2-({[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl](methyl)amino}methyl)phenyl]-4-methoxybenzenesulfonamide; phosphoric acid

N-[2-({[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl](methyl)amino}methyl)phenyl]-4-methoxybenzenesulfonamide; phosphoric acid

CAS No.:
1135280-28-2
Catalog Number:
AG008TH6
Molecular Formula:
C24H28ClN2O7PS
Molecular Weight:
554.9801
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
2mg
99%
1 week
United States
$210
- +
5mg
99%
1 week
United States
$362
- +
10mg
99%
1 week
United States
$515
- +
50mg
99%
1 week
United States
$1418
- +
Product Description
Catalog Number:
AG008TH6
Chemical Name:
N-[2-({[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl](methyl)amino}methyl)phenyl]-4-methoxybenzenesulfonamide; phosphoric acid
CAS Number:
1135280-28-2
Molecular Formula:
C24H28ClN2O7PS
Molecular Weight:
554.9801
MDL Number:
MFCD24369012
IUPAC Name:
N-[2-[[[(E)-3-(4-chlorophenyl)prop-2-enyl]-methylamino]methyl]phenyl]-4-methoxybenzenesulfonamide;phosphoric acid
InChI:
InChI=1S/C24H25ClN2O3S.H3O4P/c1-27(17-5-6-19-9-11-21(25)12-10-19)18-20-7-3-4-8-24(20)26-31(28,29)23-15-13-22(30-2)14-16-23;1-5(2,3)4/h3-16,26H,17-18H2,1-2H3;(H3,1,2,3,4)/b6-5+;
InChI Key:
XRQHWVVDNMJDEQ-IPZCTEOASA-N
SMILES:
OP(=O)(O)O.COc1ccc(cc1)S(=O)(=O)Nc1ccccc1CN(CC=Cc1ccc(cc1)Cl)C
Properties
Complexity:
700  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1  
Exact Mass:
554.104g/mol
Formal Charge:
0
Heavy Atom Count:
36  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
554.979g/mol
Monoisotopic Mass:
554.104g/mol
Rotatable Bond Count:
9  
Topological Polar Surface Area:
145A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
CaMKII inhibition hyperpolarizes membrane and blocks nitrergic IJP by closing a Cl(-) conductance in intestinal smooth muscle. American journal of physiology. Gastrointestinal and liver physiology 20120715
Examining the effect of the CaMKII inhibitor administration in the locus coeruleus on the naloxone-precipitated morphine withdrawal signs in rats. Behavioural brain research 20120115
Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. Journal of molecular and cellular cardiology 20110101
Modulations of NeuroD activity contribute to the differential effects of morphine and fentanyl on dendritic spine stability. The Journal of neuroscience : the official journal of the Society for Neuroscience 20100616
L-type Ca(2+) channel facilitation mediated by H(2)O(2)-induced activation of CaMKII in rat ventricular myocytes. Journal of molecular and cellular cardiology 20100401
CaMKII-independent effects of KN93 and its inactive analog KN92: reversible inhibition of L-type calcium channels. Biochemical and biophysical research communications 20060714
KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. The Journal of pharmacology and experimental therapeutics 20060401
Calcium signaling stimulates translation of HIF-alpha during hypoxia. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060301
CaM kinase II phosphorylation of slo Thr107 regulates activity and ethanol responses of BK channels. Nature neuroscience 20060101
Ca(2+)/calmodulin-protein kinase IIalpha in the trigeminal subnucleus caudalis contributes to neuropathic pain following inferior alveolar nerve transection. Experimental neurology 20050401
Visualization of synaptic Ca2+ /calmodulin-dependent protein kinase II activity in living neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 20050323
A CaMKII/calcineurin switch controls the direction of Ca(2+)-dependent growth cone guidance. Neuron 20040916
Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I. The Journal of biological chemistry 20040409
Roles of CaMKII, PKA, and PKC in the induction and maintenance of LTP of C-fiber-evoked field potentials in rat spinal dorsal horn. Journal of neurophysiology 20040301
Ca2+ and AMPK both mediate stimulation of glucose transport by muscle contractions. Diabetes 20040201
Reversal of morphine antinociceptive tolerance by acute spinal inhibition of Ca(2+)/calmodulin-dependent protein kinase II. European journal of pharmacology 20030328
Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse (New York, N.Y.) 20030315
Cellular mechanisms of the acute increase of glutamate release induced by nerve growth factor in rat cerebral cortex. Neuropharmacology 20030301
Calcium-calmodulin-dependent protein kinase II contributes to spinal cord central sensitization. The Journal of neuroscience : the official journal of the Society for Neuroscience 20020515
KN-93 inhibition of G protein signaling is independent of the ability of Ca2+/calmodulin-dependent protein kinase II to phosphorylate phospholipase Cbeta3 on 537-Ser. Molecular and cellular endocrinology 20010425
Properties